Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients

M Yusof Said, A Bollenbach, Isidor Minović, Marco van Londen, Anne-Roos Frenay, Martin H de Borst, Else van den Berg, A Arinc Kayacelebi, Dimitrios Tsikas, Harry van Goor, Gerjan Navis, Stephan J L Bakker

OnderzoeksoutputAcademicpeer review

12 Citaten (Scopus)
166 Downloads (Pure)

Samenvatting

Cardiovascular disease (CVD) is the leading cause of death in renal transplant recipients (RTR). Elevated plasma asymmetric dimethylarginine (pADMA), an endogenous nitric oxide synthase inhibitor produced from the turnover of methylated arginine moieties in proteins, is a risk factor for CVD and mortality. It is unknown how urinary ADMA excretion (uADMA), one of the main ADMA elimination routes, is associated with long-term survival. Furthermore, the association of pADMA and uADMA with markers for turnover of arginine-methylated proteins is unknown. We analyzed ADMA using a validated GC-MS/MS method in plasma and 24-h urine samples of 685 RTR, included1year after transplantation. We also analyzed urine symmetric dimethylarginine (uSDMA) using the same method. Urinary creatinine and urea excretions were used as markers for turnover of muscle protein and amino acids, respectively. We applied Cox regression analyses to study associations of pADMA, uADMA, and uSDMA with all-cause and CVD mortality. Mean pADMA was 0.61 +/- 0.12 mu M, uADMA was 31 +/- 13 mu mol/24h, and uSDMA was 52 +/- 19 mu mol/24h. Over median follow-up of 5.4 [4.9-6.1] years, 147 RTR died, of which 58 (39%) from CVD. High pADMA was associated with high all-cause mortality (HR per SD [95% CI]: 1.45 [1.26-1.67], P

Originele taal-2English
Pagina's (van-tot)913-927
Aantal pagina's15
TijdschriftAmino Acids
Volume51
Nummer van het tijdschrift6
DOI's
StatusPublished - jun-2019

Citeer dit